Means Investment CO. Inc. Grows Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Means Investment CO. Inc. grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 23.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,040 shares of the company’s stock after purchasing an additional 9,508 shares during the period. Means Investment CO. Inc.’s holdings in Hims & Hers Health were worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in HIMS. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the period. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the period. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the period. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Hims & Hers Health by 115.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after buying an additional 2,442 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total value of $4,276,577.98. Following the completion of the sale, the chief financial officer now owns 112,186 shares in the company, valued at $3,357,726.98. The trade was a 56.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,256,067 shares of company stock valued at $34,459,485. 17.71% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on HIMS. TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $37.33 on Monday. The firm has a market capitalization of $8.16 billion, a price-to-earnings ratio of 84.85 and a beta of 1.35. The business’s 50 day simple moving average is $29.20 and its 200-day simple moving average is $22.57. Hims & Hers Health, Inc. has a 12 month low of $8.51 and a 12 month high of $37.96.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue was up 77.1% on a year-over-year basis. During the same period last year, the company posted ($0.04) EPS. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.